ArticleJournal of Cancer2020

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.

Yangwei Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.